MetLife Investment Management LLC Buys 5,939 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV)

MetLife Investment Management LLC increased its stake in Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 65.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,993 shares of the biopharmaceutical company’s stock after buying an additional 5,939 shares during the period. MetLife Investment Management LLC’s holdings in Achieve Life Sciences were worth $71,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in Achieve Life Sciences in the third quarter worth about $54,000. The Manufacturers Life Insurance Company bought a new position in Achieve Life Sciences in the second quarter worth about $69,000. Renaissance Technologies LLC raised its stake in Achieve Life Sciences by 134.2% in the second quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 14,360 shares in the last quarter. Rhumbline Advisers bought a new position in Achieve Life Sciences in the second quarter worth about $197,000. Finally, Bank of New York Mellon Corp bought a new position in Achieve Life Sciences in the second quarter worth about $482,000. 33.52% of the stock is owned by institutional investors.

Achieve Life Sciences Trading Down 3.9 %

NASDAQ:ACHV opened at $4.38 on Wednesday. The company’s 50 day moving average price is $4.70 and its 200-day moving average price is $4.70. Achieve Life Sciences, Inc. has a 52 week low of $3.03 and a 52 week high of $5.59. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31. The stock has a market cap of $150.63 million, a price-to-earnings ratio of -3.88 and a beta of 1.58.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.10). During the same quarter in the previous year, the firm posted ($0.34) EPS. On average, equities research analysts forecast that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ACHV. Oppenheimer reissued an “outperform” rating and issued a $11.00 price target on shares of Achieve Life Sciences in a research note on Thursday, August 15th. Raymond James started coverage on shares of Achieve Life Sciences in a research note on Friday, September 27th. They set a “strong-buy” rating and a $20.00 target price for the company. RODMAN&RENSHAW raised shares of Achieve Life Sciences to a “strong-buy” rating in a research note on Thursday, November 14th. Finally, Rodman & Renshaw started coverage on shares of Achieve Life Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $12.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $14.80.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.